Douglas Jermasek
Corporate Officer/Principal bij UNICYCIVE THERAPEUTICS, INC.
Vermogen: 169 762 $ op 30-04-2024
Profiel
Douglas Jermasek currently works at Unicycive Therapeutics, Inc., as Executive Vice President-Corporate Strategy from 2021.
Mr. Jermasek also formerly worked at Deltanoid Pharmaceuticals, Inc., as Chief Executive Officer, Keryx Biopharmaceuticals, Inc., as Vice President-Marketing & Strategy from 2016 to 2018, Genzyme Corp., as Senior Vice President & General Manager, and Akebia Therapeutics, Inc., as Senior Vice President-Marketing & Strategy.
Mr. Jermasek received his undergraduate degree from Brigham Young University and Masters Business Admin degree from BYU Marriott School.
Bekende belangen in openbare bedrijven
Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
---|---|---|---|---|
15-04-2024 | 175 012 ( 0.50% ) | 169 762 $ | 30-04-2024 |
Actieve functies van Douglas Jermasek
Bedrijven | Functie | Begin |
---|---|---|
UNICYCIVE THERAPEUTICS, INC. | Corporate Officer/Principal | 26-10-2021 |
Eerdere bekende functies van Douglas Jermasek
Bedrijven | Functie | Einde |
---|---|---|
KERYX BIOPHARMACEUTICALS | Verkoop & Marketing | 12-12-2018 |
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | - |
AKEBIA THERAPEUTICS, INC. | Verkoop & Marketing | - |
Deltanoid Pharmaceuticals, Inc.
Deltanoid Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Deltanoid Pharmaceuticals, Inc. researches and develops therapies for the treatment of human diseases. The firm's focus is to move therapies in a variety of areas, including renal disease, osteoporosis, vitamin D deficiency, and acne through the drug development process and seek partners for later stage development and commercialization. The company was founded by Margaret Clagett-Dame and Hector F. DeLuca in 1999 and is headquartered in Madison, WI. | Algemeen Directeur | - |
Opleiding van Douglas Jermasek
BYU Marriott School | Masters Business Admin |
Brigham Young University | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 2 |
---|---|
UNICYCIVE THERAPEUTICS, INC. | Health Technology |
AKEBIA THERAPEUTICS, INC. | Health Technology |
Bedrijven in privébezit | 3 |
---|---|
Deltanoid Pharmaceuticals, Inc.
Deltanoid Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Deltanoid Pharmaceuticals, Inc. researches and develops therapies for the treatment of human diseases. The firm's focus is to move therapies in a variety of areas, including renal disease, osteoporosis, vitamin D deficiency, and acne through the drug development process and seek partners for later stage development and commercialization. The company was founded by Margaret Clagett-Dame and Hector F. DeLuca in 1999 and is headquartered in Madison, WI. | Commercial Services |
Keryx Biopharmaceuticals, Inc.
Keryx Biopharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Keryx Biopharmaceuticals, Inc. engaged in the manufacture, development, and commercialization of medicines for use in treating human diseases. The company was founded in August 1, 2002 and was headquartered in Cambridge, MA. | Health Technology |
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Health Technology |